Advanced search
Publication Cover
Pharmacogenomics Volume 13, 2012 - Issue 8
Submit an article Journal homepage
178
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Retrospective Evidence for Clinical Validity of Expanded Genetic model in Warfarin dose Optimization in a South Indian Population

Addepalli Pavani1 Departments of Clinical Pharmacology & Therapeutics, Nizam‘s Institute of Medical Sciences, Hyderabad, IndiaView further author information
,
Shaik Mohammad Naushad1 Departments of Clinical Pharmacology & Therapeutics, Nizam‘s Institute of Medical Sciences, Hyderabad, IndiaView further author information
,
Ramesh C Mishra2 Cardiothoracic Surgery, Nizam‘s Institute of Medical Sciences, Hyderabad, IndiaView further author information
,
Amaresh Rao Malempati2 Cardiothoracic Surgery, Nizam‘s Institute of Medical Sciences, Hyderabad, IndiaView further author information
,
Ramakrishna Pinjala3 Vascular Surgery, Nizam‘s Institute of Medical Sciences, Hyderabad, IndiaView further author information
,
Takallapally Ramesh Kumar1 Departments of Clinical Pharmacology & Therapeutics, Nizam‘s Institute of Medical Sciences, Hyderabad, IndiaView further author information
&
Vijay Kumar Kutala1 Departments of Clinical Pharmacology & Therapeutics, Nizam‘s Institute of Medical Sciences, Hyderabad, IndiaCorrespondence[email protected]
View further author information
 show all
Pages 869-878 | Published online: 07 Jun 2012

References

  • Hirsh J , FusterV, AnsellJ, HalperinJL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J. Am. Coll. Cardiol.107 , 1633–1652 (2003).
  • Van Walraven C , JenningsA, OakeN, FergussonD, ForsterAJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest129 , 1155–1166 (2006).
  • Budnitz DS , PollockDA, WeidenbachK, MendelsohnAB, SchroederTJ, AnnestJL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA296 , 1858–1866 (2006).
  • Finkelman BS , GageBF, JohnsonJA, BrensingerCM, KimmelSE. Genetic warfarin dosing: tables versus algorithms. J. Am. Coll. Cardiol.57 , 612–618 (2011).
  • Avery PJ , JorgensenA, HambergAK, WadeliusM, PirmohamedM, KamaliF. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin. Pharmacol. Ther.90 , 701–706 (2011).
  • Biss TT , AveryPJ, BrandãoLR et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood119(3) , 868–873 (2011).
  • Xu H , JiangM, OetjensM et al. Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. J. Am. Med. Inform. Assoc. 18 , 387–391 (2011).
  • Zhu Y , ShennanM, ReynoldsKK et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chem. 53 , 1199–1205 (2007).
  • Wadelius M , ChenLY, LindhJD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113 , 784–792 (2009).
  • Klein TE , AltmanRB, ErikssonN et al.; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360 , 753–764 (2009).
  • Pavani A , NaushadSM, RupasreeY et al. Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenomics J. doi:10.1038/tpj.2011.4 (2011) (Epub ahead of print).
  • Mitchell C , GregersenN, KrauseA. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics12 , 953–963 (2011).
  • Kimura R , MiyashitaK, KokuboY et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb. Res. 120 , 181–186 (2007).
  • McDonald MG , RiederMJ, NakanoM, HsiaCK, RettieAE. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol.75 , 1337–1346 (2009).
  • Dang MT , HambletonJ, KayserSR. The influence of ethnicity on warfarin dosage requirement. Ann. Pharmacother.39 , 1008–1012 (2005).
  • Garcia D , ReganS, CrowtherM, HughesRA, HylekEM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest127 , 2049–2056 (2005).
  • Namazi S , AzarpiraN, HendijaniF et al. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. Clin. Ther. 32 , 1050–1060 (2010).
  • Rathore SS , AgarwalSK, PandeS, MittalT, MittalB. Frequencies of VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population. Biosci. Trends4 , 333–337 (2010).
  • Ohno M , YamamotoA, OnoA et al. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur. J. Clin. Pharmacol. 65 , 1097–1103 (2009).
  • Yuen E , GueorguievaI, WiseS, SoonD, AaronsL. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J. Pharmacokinet. Pharmacodyn.37 , 3–24 (2010).
  • Takeuchi F , McGinnisR, BourgeoisS et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5 , e1000433 (2009).
  • Loebstein R , DvoskinI, HalkinH et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109 , 2477–2480 (2007).
  • Zhu J , ZhangW, LiY et al. ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese. Pharmacogenomics 11 , 113–119 (2010).
  • Chan SL , SuoC, LeeSC et al. Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. Pharmacogenomics J. doi:10.1038/tpj.2011.7 (2011) (Epub ahead of print).
  • Shahin MH, Khalifa SI, Gong Y et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet. Genomics21 , 130–135 (2011).
  • Kurnik D , LoebsteinR, FarfelZ, EzraD, HalkinH, OlchovskyD. Complex drug–drug–disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore)83 , 107–113(2004).
  • Bucerius J , JoeAY, PalmedoH, ReinhardtMJ, BiersackHJ. Impact of short-term hypothyroidism on systemic anticoagulation in patients with thyroid cancer and coumarin therapy. Thyroid16 , 369–374 (2006).
  • Demirkan K , StephensMA, NewmanKP, SelfTH. Response to warfarin and other oral anticoagulants: effects of disease states. South Med J.93 , 448–454 (2000).
  • Chute JP , RyanCP, SladekG, ShakirKM. Exacerbation of warfarin-induced anticoagulation by hyperthyroidism. Endocr. Pract.3 , 77–79 (1997).
  • Van Oosterom AT , MattieH, HermensWT, VeltkampJJ. The influence of the thyroid function on the metabolic rate of prothrombin, factor VII, and factor X in the rat. Thromb. Haemost.35 , 607–619 (1976).
  • Gong IY , TironaRG, SchwarzUI et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118 , 3163–7311 (2011).
  • Anderson JL , HorneBD, StevensSM et al.; Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation116 , 2563–2570 (2007).
  • Seckeler MD , HokeTR. The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. Clin. Epidemiol.3 , 67–84 (2011).
  • Shikata E , IeiriI, IshiguroS et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103 , 2630–2635 (2004).
  • - SchellemanH, BrensingerCM, ChenJ, FinkelmanBS, RiederMJ, KimmelSE. New genetic variant that might improve warfarin dose prediction in African Americans. Br. J. Clin. Pharmacol.70 , 393–399 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.